Tuarascálacha Rannán na Seirbhísí - St. James's Hospital

FoilseacháinRichardson, KJ O’Byrne.Epidermal growth factor receptor (EGFR) andCyclooxygenase (COX)-2 in non-small cell lungcancer (NSCLC). Growth factors and cytokinesenhance the in vitro anti-tumour activity of selectiveEGFR and/or COX-2 inhibitors.Proc Am Soc Clin Oncol 2003: 22: abstract 2629(Poster)C Richardson, D Swinson, D Richardson, W A Swain, KJO’Byrne.Phase II open-label study of MEN 10755 in patientswith small cell lung cancer extensive disease (SCLC-ED).Proc Am Soc Clin Oncol 2003; 22: abstract 2829N Dickgreber, T Welte, A Gillissen, D Dunlop, WEberhardt, T Wagner, D Swinson, A Capriati, K J O’ByrneTolerability of the novel oral thalidomide analog CC-5013 demonstrating extensive immune activationand clinical response.Proc Am Soc Clin Oncol 2003; 22: abstract 2862 (Posterdiscussion)R Sharma, J Marriott, I Clarke, L Cohen, W Steward, KJO’Byrne, A DalgleishMicroarray analysis of mesothelial cells treated withcrocidolite, erionite, IL-1beta and TNF-alpha. (Oralpresentation World Conference on Lung Cancer[WCLC])Lung Cancer 2003; 41 (suppl 2): S25W Swain, L Sander, T Gant, S Faux, KJ O’ByrneImproved quality of life with the addition of SRL172(killed mycobacterium vaccae) to standardchemotherapy in patients with advanced non-smallcell lung cancer: Phase III results. (Oral presentationWCLC)Lung Cancer 2003; 41 (suppl 2): S35M O’Brien, H Anderson, E Khaukel, KJ O’Byrne, MPawlicki, J Von Pawel, M ReckClinical Evaluation of gefitinib (Iressa ZD1839) incombination with Rofecoxib in cisplatin pre-treatedrelapsed non-small cell lung cancer. (Oralpresentation WCLC)Lung Cancer 2003; 41 (suppl 2): S36KJ O’Byrne, L Clarke, D Dunlop, M Ranson, S Danson, NBotwood.Tumour necrosis factor-alpha cell signalling events inhuman bronchoepithelial cells. (Oral presentationWCLC)Lung Cancer 2003; 41 (suppl 2): S43W A Swain, KJ O’Byrne.D Dunlop, D Roitman, Y Alan, D Walde et al. Resultsof phase II trial of EGF-P64 vaccine in patients withadvanced non-small cell lung cancer. (Oralpresentation WCLC)Lung Cancer 2003; 41 (suppl2): S47M Vincent, C Smith, R Milroy, KJ O’Byrne,Randomised Phase II clinical trial of cetuximab incombination with cisplatin and vinorelbine orcisplatin and vinorelbine alone in patients withadvanced epidermal growth factor receptor (EGFR)-positive non small cell lung cancer (NSCLC). (Oralpresentation); ECCOLung Cancer 2003; 41 (suppl 2): S72R Rosell, M Constenla, R Kolb, W Pfeiffer, KJ O’Byrne, RPirker et al.Selective Cyclooxygenase (COX)-2 inhibitors incombination with cytokines induce growth arrest innon-small cell lung cancer lines at clinically relevantdoses.Lung Cancer 2003; 41 (suppl 2): S174 (Poster WCLC)C Richardson, D Swinson, D Kaur, A Shah, D Richardson,KJ O’Byrne.The expression and prognostic significance of Aktand phosphorylated Akt (pAkt) in non-small cell lungcancer.Lung Cancer 2003; 41 (suppl 2): S212 (Poster WCLC)A Shah, C Richardson, D Richardson, W A Swain, DSwinson, KJ O’Byrne.Hypoxia inducible factor-1 alpha in non-small celllung cancer: Relation to other biological factors andprognosis.Lung Cancer 2003; 41 (suppl 2): S214 (Poster WCLC).D Swinson, L Jones, G Cox, D Richardson, A Harris, KJO’ByrneThe History of Bone Marrow Transplantation.In; History of Organ and Cell Transplantation. Eds NSHakim and VE Papalois. Imperial College Press. 2003.McCann S.Vascular endothelial growth factor in lung cancerLung Cancer edited by Barbara Driscoll. Humana Press(2003), Volume 1, section E, chapter 21, pp357-374.84 84